Rheumatoid Arthritis

Question 1

Most common form of chronic inflammatory arthritis

Answer 1

Symmetric polyarthritis

Question 2

In RA, Anti-CCPs serve as the ff except
A. Diagnostic evaluation 
B. Prognostication
C. Monitor relapse
D. None of the above

Answer 2

C.

Question 3

Most common valvular abnormality in RA

A. Mitral regurgitation
B. Mitral stenosis
C. Tricuspid stenosis
D. Aortic regurgitation

Answer 3

A

Question 4

Most common hematologic abnormality in RA

Answer 4

Normochromic, normocytic anemia

Question 5

Most common pulmonary manifestation of RA

Answer 5

Pleuritis

Question 6

Most common cause of death in RA

Answer 6

Cardiovascular disease

Question 7

overwhelming cell type in the synovial fluid of RA

Answer 7

neutrophil,

Question 8

DMARD of first choice for the initial treatment of moderate to severe RA
A. Methotrexate
B.  Hydroxychloroquine
C. Sulfasalazine
D. Leflunomide

Answer 8

methotrexate

Question 9

Onset of action of conventional DMARDs

Answer 9

~6-12 weeks

hydroxychloroquine, sulfasalazine, methotrexate, and leflunomide

Question 10

Methotrexate’s action at dosages used for the treatment of RA

Answer 10

methotrexate has been shown to stimulate adenosine release from cells, producing an anti-inflammatory effect.

Question 11

Anti-TNF agents (5)

Answer 11

Infliximab
adalimumab
golimumab
Certolizumab
etanercept

Question 12

Which is a chimeric monoclonal antibody?
A. Certolizumab
B. Infliximab
C. Adalimumab
D. Golimumab

Answer 12

B. Infliximab

Question 13

pegylated Fc-free fragment of a humanized monoclonal antibody with binding specificity for TNF-α

Answer 13

Certolizumab pegol

Question 14

A soluble fusion protein comprising the TNF receptor 2 in covalent linkage with the Fc portion of IgG1

Answer 14

Etanercept

Question 15

Anti-TNF agents pproved for use as monotherapy, except
A. Etanercept
B. Adalimumab
C. certolizumab pegol
D. Infliximab

Answer 15

D.

Monotherapy: Etanercept, adalimumab, certolizumab pegol, and golimumab

Question 16

Major concern in Anti-TNF agents use

Answer 16

Increased risk of infection

Serious bacterial infections, opportunistic fungal infection, and reactivation of latent tuberculosis

Question 17

IL-1 receptor antagonist
A. Rituximab
B. Tocilizumab
C. Abatecept
D. Anakinra

Answer 17

D. Anakinra

A. Rituximab-anti CD20
B. Tocilizumab-anti IL-6
C. Abatecept-fusion protein linked to the modified por- tion of human IgG

Question 18

Should not be combined with an anti-TNF drug due to the high rate of serious infections observed with this regimen
A. Anakinra
B. Tocilizumab
C. Abatecept
D. Rituximab

Answer 18

A. Anakinra

Question 19

Small-molecule inhibitor that primarily inhibits JAK1 and JAK3, which mediate signaling of the receptors for the common γ-chain-related cytokines IL-2, 4, 7, 9, 15, and 21 as well as IFN-γ and IL-6
A. Anakinra
B. Tofacitinib
C. Abatecept
D. Rituximab

Answer 19

B. Tofacitinib

Question 20

Used for treatment of RA-ILD with high dose corticosteroids, except
A. azathioprine
B. tofacitinib
C. mycophenolate mofetil
D. rituximab

Answer 20

Adjunctive immu- nosuppressive agents, such as azathioprine, mycophenolate mofetil, and rituximab

Question 21

How is Simplified Disease Activity Index score (SDAI) calculated?

Answer 21

Sum of a tender joint and swollen joint count (using 28 joints), patient global assessment (0–10 scale), phy- sician global assessment (0–10 scale), and CRP (in mg/dL)

Question 22

ACR/EULAR Provisional Definition of Remission in Rheumatoid Arthritis

Answer 22

Simplified Disease Activity Index score of ≤3.3
OR
Tender joint count ≤1
Swollen joint count ≤1
C-reactive protein ≤1 mg/dL
Patient global assessment ≤1 (on a 0–10 scale)

Question 23

Most common prosthetic for MCP arthroplasty

Answer 23

Silicone implants

Question 24

Most common form of lymphoma in RA

Answer 24

Diffuse large B-cell lymphoma